Status:

COMPLETED

Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.

Lead Sponsor:

Eli Lilly and Company

Collaborating Sponsors:

Boehringer Ingelheim

Conditions:

Urinary Incontinence, Stress

Eligibility:

FEMALE

18+ years

Phase:

PHASE3

Brief Summary

The purpose of the study is to evaluate the effectiveness of duloxetine in reducing urinary incontinence(leakage of urine)occurrences in women due to physical stress and leakage that occurs during a s...

Eligibility Criteria

Inclusion

  • female outpatients greater than or equal to 18 years of age.
  • experience episodes of urinary incontinence based on diagnostic criteria of at least 4 episodes a week with symptoms for a minimum of three months prior to start of study.
  • have an educational level and degree of understanding English.
  • are free of urinary tract infections.
  • have a discreet episodes of incontinence(i.e. dry between episodes and do not continuously leak.)

Exclusion

  • have received treatment for incontinence within the last 5 years.
  • suffer from severe constipation.
  • currently nursing or breast feeding.
  • any nervous system disease that would affect normal urinary function.
  • any extension of internal organs beyond the vaginal opening.

Key Trial Info

Start Date :

September 1 2003

Trial Type :

INTERVENTIONAL

End Date :

May 1 2006

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT00190814

Start Date

September 1 2003

End Date

May 1 2006

Last Update

January 26 2007

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559), Monday-Friday, 9 am to 5 pm Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician

Baltimore, Maryland, United States, 21204

2

For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559), Monday-Friday, 9 am to 5 pm Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician

London, Ontario, Canada, N6A 4L2

3

For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559), Monday-Friday, 9 am to 5 pm Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician

London, United Kingdom, W2 1NY